Tunicamycin, which was proven in our experiments to diminish CD147 glycosylation, also suppressed the increases in MMP2/9 expression and activity in response to HG and CML (Figure 6A–D) confirming the role of the glycosylated CD147 in MMP induction. This evidence concerns the gene BSG and chronic myelogenous leukemia, BCR-ABL1 positive.